Bortezomib-induced peripheral neuropathy : Clinical features, molecular basis, and therapeutic approach
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved..
Bortezomib is the first-line standard and most effective chemotherapeutic for multiple myeloma; however, bortezomib-induced peripheral neuropathy (BIPN) severely affects the chemotherapy regimen and has long-term impact on patients under maintenance therapy. The pathogenesis of BIPN is poorly understood, and basic research and development of BIPN management drugs are in early stages. Besides chemotherapy dose reduction and regimen modification, no recommended prevention and treatment approaches are available for BIPN apart from the International Myeloma Working Group guidelines for peripheral neuropathy in myeloma. An in-depth exploration of the pathogenesis of BIPN, development of additional therapeutic approaches, and identification of risk factors are needed. Optimizing effective and standardized BIPN treatment plans and providing more decision-making evidence for clinical diagnosis and treatment of BIPN are necessary. This article reviews the recent advances in BIPN research; provides an overview of clinical features, underlying molecular mechanisms, and therapeutic approaches; and highlights areas for future studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:197 |
|---|---|
| Enthalten in: |
Critical reviews in oncology/hematology - 197(2024) vom: 13. Apr., Seite 104353 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Yang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bortezomib-induced peripheral neuropathy |
|---|
| Anmerkungen: |
Date Revised 17.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.critrevonc.2024.104353 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371051940 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371051940 | ||
| 003 | DE-627 | ||
| 005 | 20240418233037.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240415s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2024.104353 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1379.xml |
| 035 | |a (DE-627)NLM371051940 | ||
| 035 | |a (NLM)38615869 | ||
| 035 | |a (PII)S1040-8428(24)00096-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Yang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bortezomib-induced peripheral neuropathy |b Clinical features, molecular basis, and therapeutic approach |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Bortezomib is the first-line standard and most effective chemotherapeutic for multiple myeloma; however, bortezomib-induced peripheral neuropathy (BIPN) severely affects the chemotherapy regimen and has long-term impact on patients under maintenance therapy. The pathogenesis of BIPN is poorly understood, and basic research and development of BIPN management drugs are in early stages. Besides chemotherapy dose reduction and regimen modification, no recommended prevention and treatment approaches are available for BIPN apart from the International Myeloma Working Group guidelines for peripheral neuropathy in myeloma. An in-depth exploration of the pathogenesis of BIPN, development of additional therapeutic approaches, and identification of risk factors are needed. Optimizing effective and standardized BIPN treatment plans and providing more decision-making evidence for clinical diagnosis and treatment of BIPN are necessary. This article reviews the recent advances in BIPN research; provides an overview of clinical features, underlying molecular mechanisms, and therapeutic approaches; and highlights areas for future studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Bortezomib-induced peripheral neuropathy | |
| 650 | 4 | |a Clinical features | |
| 650 | 4 | |a Pathogenesis | |
| 650 | 4 | |a Therapeutic drug development | |
| 700 | 1 | |a Zhao, Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Lan, Hongli |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Jinbing |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Guoli |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical reviews in oncology/hematology |d 1996 |g 197(2024) vom: 13. Apr., Seite 104353 |w (DE-627)NLM012606006 |x 1879-0461 |7 nnns |
| 773 | 1 | 8 | |g volume:197 |g year:2024 |g day:13 |g month:04 |g pages:104353 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.critrevonc.2024.104353 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 197 |j 2024 |b 13 |c 04 |h 104353 | ||